ALLAKOS
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.
ALLAKOS
Social Links:
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2012-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.allakos.com
Total Employee:
101+
Status:
Active
Contact:
650-597-5002
Email Addresses:
[email protected]
Total Funding:
312.45 M USD
Technology used in webpage:
Domain Not Resolving Google Maps IPv6 Google Google Maps API CloudFront Invalid Certificate Dates Mobile Optimized New Relic QUIC
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Pleno
Pleno is a biotechnology company that aims speeding up disease diagnosis and treatment.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Alta Partners
Alta Partners investment in Post-IPO Equity - Allakos
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Allakos
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Allakos
Frazier Life Sciences
Frazier Life Sciences investment in Post-IPO Equity - Allakos
TCG Crossover
TCG Crossover investment in Post-IPO Equity - Allakos
Logos Capital
Logos Capital investment in Post-IPO Equity - Allakos
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Allakos
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Allakos
RTW Investments
RTW Investments investment in Post-IPO Equity - Allakos
Braidwell
Braidwell investment in Post-IPO Equity - Allakos
Official Site Inspections
http://www.allakos.com Semrush global rank: 4.84 M Semrush visits lastest month: 1.8 K
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Allakos"
Management team for Allakos
Prior to joining Allakos, Dr. Tomasi was Chief Scientific Officer and Head of Corporate Development at ZS Pharma where he led scientific, business development, and investor …See details»
Allakos │ Therapeutic antibodies │ Mast cells and Eosinophils
Allakos is a clinical-stage company developing monoclonal antibodies that target immunomodulatory receptors present on the surface of immune effector cells. Overview. We …See details»
Allakos - Crunchbase Company Profile & Funding
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases …See details»
Allakos Inc Company Profile - Allakos Inc Overview - GlobalData
Allakos Inc (Allakos) is a clinical-stage biotechnology company that develops antibodies that target immunomodulatory receptors present on immune effector cells. The company …See details»
Allakos Inc. (ALLK) Company Profile & Overview - Stock Analysis
Jul 19, 2018 Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, …See details»
Allakos Inc. (ALLK) Company Profile & Facts - Yahoo Finance
See the company profile for Allakos Inc. (ALLK) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Allakos Company Profile - Office Locations, Competitors ... - Craft
Aug 2, 2024 Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is …See details»
Allakos - Funding, Financials, Valuation & Investors - Crunchbase
Aug 27, 2020 Allakos is registered under the ticker NASDAQ:ALLK . Their stock opened with $18.00 in its Jul 23, 2018 IPO. Stock Symbol NASDAQ:ALLK ; Valuation at IPO $728M; …See details»
Allakos - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Allakos . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Allakos has 7 current employee profiles, including …See details»
Allakos Provides Business Update and Reports Third Quarter 2023 ...
Nov 13, 2023 Upcoming Allakos Anticipated Milestones Topline data expected from the Phase 2 study of subcutaneous lirentelimab in patients with atopic dermatitis in late Q4 2023 to Q1 2024.See details»
Board of Directors - Allakos
During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and …See details»
Allakos Announces a Restructuring to Focus on Development of …
Jan 16, 2024 Anticipated Allakos Milestones. Q1 2024: Complete dosing in the single ascending dose (SAD) and multiple ascending dose (MAD) cohorts of the randomized, double-blind, …See details»
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
Nov 11, 2024 Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the …See details»
Allakos Provides Business Update and Reports Fourth Quarter and …
Mar 14, 2024 Upcoming Allakos Anticipated Milestones. Report safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of IV AK006 in healthy volunteers, …See details»
Allakos Inc. (ALLK) Stock Price, Quote & News - Stock Analysis
Nov 18, 2024 Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, …See details»
Scientific Advisors - Allakos
Dr. Bochner is a co-founder of Allakos and has been a member of its Scientific Advisory Board since 2012. Dr. Bochner is a physician-scientist and co-discoverer of Siglec-8. His NIH-funded …See details»
Allakos Announces Positive Results from its Ongoing Phase 1 Trial …
Jun 25, 2024 These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking …See details»
Head of Human Resources - Allakos
Allakos is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in …See details»